Oxxon Therapeutics

Oxxon Therapeutics was a clinical-stage biotechnology company specializing in the development of "PrimeBoost" immunotherapies for the treatment of chronic infectious diseases and cancer. The company's proprietary technology platform utilized a sequential administration of different vaccine delivery systems, such as DNA and viral vectors, to generate potent T-cell responses. Its lead candidate, Hi-8, was a therapeutic vaccine for melanoma that reached Phase 2 clinical trials. Oxxon was headquartered in Oxford, UK, with operations in Boston, Massachusetts. In 2007, the company was acquired by Oxford BioMedica to bolster its immunotherapy pipeline and expertise.